Prognostic factors in squamous cell lip carcinoma treated with high‐dose‐rate brachytherapy

Guinot, J.L.; Arribas, L.; Vendrell, Juan Bosco; Santos, Miguel; Tortajada, M.I.; Mut, Alejandro; Cruz, Julia; Mengual, J.; Chust, M.

doi:10.1002/hed.23529

Cited by 28 publications

(19 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[69][70][71] Far less data are available on the outcome of elective lymph node basin RT, but the existing series have generally used a dose of 5000 cGy at 200 cGy/fraction or an equivalent regimen (ie, 5400 cGy at 180 cGy/ fraction). 23,25,26,[56][57][58][59][60][61][62][63][64][65][66][67][68] Key Question 4: Radiation techniques and dose-fractionation schedules for primary site management (Table 5) See online data supplement (Guideline Evidence Tables, available online at https://doi.org/10.1016/j. prro.2019.10.014) for the evidence supporting the recommendations for KQ4.…”

Section: Key Questions and Recommendationsmentioning

confidence: 99%

“…Megavoltage (MV) electrons, brachytherapy (low-dose-rate and high-dose-rate [HDR]), kilovoltage, and MV photons have been successfully used to treat BCC and cSCC. 6,65,78,84,85 A thorough literature review on this topic suggests that appropriate use of any of the 4 major radiation modalities results in similar local control and cosmetic outcome. 3,4,9,28,31,[64][65][66]68,[72][73][74][75][76][77][78][79][80][81][82][83][84][86][87][88] Thus, the decision of which modality and fractionation scheme to use should be based on both tumor characteristics (eg, shape, contour, depth, and location) and normal tissue considerations.…”

Section: Key Questions and Recommendationsmentioning

confidence: 99%

See 1 more Smart Citation

Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin: Executive Summary of an American Society for Radiation Oncology Clinical Practice Guideline

Likhacheva

Awan

Barker

et al. 2020

Practical Radiation Oncology

138

158

View full text Add to dashboard Cite

Merck; past honoraria and travel expenses from the National Comprehensive Cancer Network; a past advisory board position with Regeneron; and past honoraria from the University of Florida and University of Rochester. Dr Bhatnagar reports a position of state chapter president for the Arizona Radiologic Society; stock with Cancer Treatment Services International; and consulting and research for Icad. Dr Devlin is the task force chair and reports membership of the Massachusetts Medical Society Finance and Audit Committee and past honoraria, travel expenses, and advisory board membership for Sirtex. Dr Geiger, an American Society of Clinical Oncology representative, reports research and advisory board membership for Regeneron and research for Genentech/Roche. Dr Likhacheva is task force vice chair and reports spouse employment with Reflexion and travel expenses from the Russian Society of Clinical Oncology. Drs Brady (Society of Surgical Oncology representative), Buzurovic, Parvathaneni, and Zaky reported no disclosures. Disclaimer and Adherence: American Society for Radiation Oncology (ASTRO) guidelines present scientific, health, and safety information and may reflect scientific or medical opinion. They are available to ASTRO members and the public for educational and informational purposes only. Commercial use of any content in this guideline without the prior written consent of ASTRO is strictly prohibited. Adherence to this guideline does not ensure successful treatment in every situation. This guideline should not be deemed inclusive of all proper methods of care or exclusive of other methods reasonably directed to obtaining the same results. The physician must make the ultimate judgment regarding therapy considering all circumstances presented by the patient. ASTRO assumes no liability for the information, conclusions, and findings contained in its guidelines. This guideline cannot be assumed to apply to the use of these interventions performed in the context of clinical trials. This guideline is based on information available at the time the task force conducted its research and discussions on this topic. There may be new developments that are not reflected in this guideline and that may, over time, be a basis for ASTRO to revisit and update the guideline.

show abstract

Section: Key Questions and Recommendationsmentioning

confidence: 99%

Section: Key Questions and Recommendationsmentioning

confidence: 99%

Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin: Executive Summary of an American Society for Radiation Oncology Clinical Practice Guideline

Likhacheva

Awan

Barker

et al. 2020

Practical Radiation Oncology

138

158

View full text Add to dashboard Cite

show abstract

“…Guinot et al compared 99 LDR cases and 104 HDR cases with similar local control (95%) but fewer complications using HDR and no case of bone or soft tissue necrosis in the last group [31]. PDR is effective with local control of 94% [32] Most cases are treated with brachytherapy alone although elective cervical treatment should be considered in lip tumors larger than 2 cm or with skin or commissure involvement [33].…”

Section: Lip Cancermentioning

confidence: 99%

GEC-ESTRO ACROP recommendations for head & neck brachytherapy in squamous cell carcinomas: 1st update – Improvement by cross sectional imaging based treatment planning and stepping source technology

Kovács

Martı́nez-Monge

Budrukkar

et al. 2017

Radiotherapy and Oncology

122

View full text Add to dashboard Cite

The Head and Neck Working Group of the GEC-ESTRO (Groupe Européen de Curiethérapie - European Society for Therapeutic Radiology and Oncology) published in 2009 the consensus recommendations for low-dose rate, pulsed-dose rate and high-dose rate brachytherapy in head & neck cancers. The use of brachytherapy in combination with external beam radiotherapy and/or surgery was also covered as well as the use of brachytherapy in previously irradiated patients. Given the developments in the field, these recommendations needed to be updated to reflect up-to-date knowledge. The present update does not repeat basic knowledge which was published in the first recommendation but covers in a general part developments in (1) dose and fractionation, (2) aspects of treatment selection for brachytherapy alone versus combined BT+EBRT and (3) quality assurance issues. Detailed expert committee opinion intends to help the clinical practice in lip-, oral cavity-, oropharynx-, nasopharynx-, and superficial cancers. Different aspects of adjuvant treatment techniques and their results are discussed, as well the possibilities of salvage brachytherapy applications.

show abstract

“…HDR-IRT provided excellent results in a large cohort of patients with lip cancer, as local control rates were 100% in T1, 93.9% in T2, and 80% in T4 cancers. Unfortunately no information was available on age-related outcomes in this study [ 94 ].…”

Section: Resultsmentioning

confidence: 99%

Age Is Not a Limiting Factor in Interventional Radiotherapy (Brachytherapy) for Patients with Localized Cancer

Lancellotta

Kovács

Tagliaferri

et al. 2018

BioMed Research International

View full text Add to dashboard Cite

This review examines the role of interventional radiotherapy (IRT otherwise known as brachytherapy) in cancer treatment for elderly patients. Despite their advanced age and associated comorbidities, elderly patients should receive definitive cancer therapies, including surgery and radiotherapy (RT). In fact, RT becomes first-line option for patients who are not eligible for surgery (due to comorbidities, anticoagulant drugs, and risk of disfigurement) or those who refuse it. It emerged from this review of the literature as effective, simple, safe, and comfortable and was associated with good local control, low toxicity rates, and excellent cosmesis and provided a cost benefit. IRT may be used as sole treatment for small cancers or as a useful adjunct to surgery or external beam radiotherapy (EBRT) in more advanced (or lymph node positive) cases, especially when the aim is local control with adequate preservation of normal tissue function. As palliative treatment, IRT preserves quality of life and/or improves survival. It is to be hoped that this review will serve as a helpful guide for members of multidisciplinary teams that are involved in treating elderly patients with cancer.

show abstract

Prognostic factors in squamous cell lip carcinoma treated with high‐dose‐rate brachytherapy

Abstract: HDR-brachytherapy yields excellent local control rates. Skin involvement increases the risk of local and cervical recurrence. Elective neck treatment should be done in T2 to T4 tumors or with skin or commissure involvement.

Cited by 28 publications

References 34 publications

Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin: Executive Summary of an American Society for Radiation Oncology Clinical Practice Guideline

Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin: Executive Summary of an American Society for Radiation Oncology Clinical Practice Guideline

GEC-ESTRO ACROP recommendations for head & neck brachytherapy in squamous cell carcinomas: 1st update – Improvement by cross sectional imaging based treatment planning and stepping source technology

Age Is Not a Limiting Factor in Interventional Radiotherapy (Brachytherapy) for Patients with Localized Cancer

Contact Info

Product

Resources

About